JAMA Dermatology

<jats:sec id="ab-doi230059-4"><jats:title>Importance</jats:title><jats:p>Biologics used for plaque psoriasis have been reported to be associated with an atopic dermatitis (AD) phenotype, or paradoxical eczema, in some patients. The risk factors for this are unknown.</jats:p></jats:sec><jats:sec id="ab-doi230059-5"><jats:title>Objective</jats:title><jats:p>To explore risk of paradoxical eczema by biologic class and identify factors associated with paradoxical eczema.</jats:p></jats:sec><jats:sec id="ab-doi230059-6"><jats:title>Design, Setting, and Participants</jats:title><jats:p>This prospective cohort study used data from the British Association of Dermatologists Biologics and Immunomodulators Register for adults treated with biologics for plaque psoriasis who were seen at multicenter dermatology clinics in the UK and Ireland. Included participants were registered and had 1 or more follow-up visits between September 2007 and December 2022.</jats:p></jats:sec><jats:sec id="ab-doi230059-7"><jats:title>Exposures</jats:title><jats:p>Duration of exposure to tumor necrosis factor (TNF) inhibitors, interleukin (IL) 17 inhibitors, IL-12/23 inhibitors, or IL-23 inhibitors until paradoxical eczema onset, treatment discontinuation, last follow-up, or death.</jats:p></jats:sec><jats:sec id="ab-doi230059-8"><jats:title>Main Outcomes and Measures</jats:title><jats:p>Incidence rates of paradoxical eczema, paradoxical eczema risk by biologic class, and the association of demographic and clinical variables with risk of paradoxical eczema were assessed using propensity score–weighted Cox proportional hazards regression models.</jats:p></jats:sec><jats:sec id="ab-doi230059-9"><jats:title>Results</jats:title><jats:p>Of 56 553 drug exposures considered, 24 997 from 13 699 participants were included. The 24 997 included exposures (median age, 46 years [IQR, 36-55 years]; 57% male) accrued a total exposure time of 81 441 patient-years. A total of 273 exposures (1%) were associated with paradoxical eczema. The adjusted incidence rates were 1.22 per 100 000 person-years for IL-17 inhibitors, 0.94 per 100 000 person-years for TNF inhibitors, 0.80 per 100 000 person-years for IL-12/23 inhibitors, and 0.56 per 100 000 person-years for IL-23 inhibitors. Compared with TNF inhibitors, IL-23 inhibitors were associated with a lower risk of paradoxical eczema (hazard ratio [HR], 0.39; 95% CI, 0.19-0.81), and there was no association of IL-17 inhibitors (HR, 1.03; 95% CI, 0.74-1.42) or IL-12/23 inhibitors (HR, 0.87; 95% CI, 0.66-1.16) with risk of paradoxical eczema. Increasing age (HR, 1.02 per year; 95% CI, 1.01-1.03) and history of AD (HR, 12.40; 95% CI, 6.97-22.06) or hay fever (HR, 3.78; 95% CI, 1.49-9.53) were associated with higher risk of paradoxical eczema. There was a lower risk in males (HR, 0.60; 95% CI, 0.45-0.78).</jats:p></jats:sec><jats:sec id="ab-doi230059-10"><jats:title>Conclusions and Relevance</jats:title><jats:p>In this study, in biologic-treated patients with psoriasis, paradoxical eczema risk was lowest in patients receiving IL-23 inhibitors. Increasing age, female sex, and history of AD or hay fever were associated with higher risk of paradoxical eczema. The overall incidence of paradoxical eczema was low. Further study is needed to replicate these findings.</jats:p></jats:sec>

Psoriasis: classical vs. paradoxical: the yin-yang of TNF and type I interferon.

Front Immunol

Biologic agent–associated cutaneous adverse events: a single center experience.

Clin Med Res

Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.

Br J Dermatol

Disease concomitance in psoriasis.

J Am Acad Dermatol

Mutual antagonism of T cells causing psoriasis and atopic eczema.

N Engl J Med

Genome-wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms.

Am J Hum Genet

Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis.

Nat Genet

Can atopic eczema and psoriasis coexist? a systematic review and meta-analysis.

Skin Health Dis

Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.

Pediatr Dermatol

Review of dupilumab-associated inflammatory arthritis: an approach to clinical analysis and management.

JAAD Case Rep

The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives.

Risk of serious infection in patients with psoriasis receiving biologic therapies: a prospective cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

J Invest Dermatol

Regression models and life-tables.

J R Stat Soc B

An introduction to propensity score methods for reducing the effects of confounding in observational studies.

Multivariate Behav Res

The central role of the propensity score in observational studies for causal effects.

Biometrika

Variable selection for propensity score models.

Am J Epidemiol

Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls.

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J).

J Dermatol

Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.

Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies.

Drugs Aging

Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.

Eczema as an adverse effect of anti-TNFa therapy in psoriasis and other Th1-mediated diseases: a review.

J Dermatolog Treat

Concurrence of psoriasis vulgaris and atopic eczema in a single patient exhibiting different expression patterns of psoriatic autoantigens in the lesional skin.

Mixed profile of cytokines in paradoxical eczematous eruptions associated with anti-IL-17 therapy.

J Allergy Clin Immunol Pract

Integrated safety analysis of treatment-emergent eczematous reactions in patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept and ustekinumab.

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.

Clin Gastroenterol Hepatol

Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients.

Dermatology

Atopic polygenic risk score is associated with paradoxical eczema developing in psoriasis patients treated with biologics.

Filaggrin mutations, atopic eczema, hay fever, and asthma in children.

J Allergy Clin Immunol

Prevalence and characteristics of atopic dermatitis among young adult females and males—report from the Swedish population-based study BAMSE.

J Eur Acad Dermatol Venereol

Effects of cyclosporine A on T cell development and clonal deletion.

Science

Inhibitory effects of cyclosporine on human regulatory T cells in vitro.

Transplant Proc

Biologics used for plaque psoriasis have been reported to be associated with an atopic dermatitis (AD) phenotype, or paradoxical eczema, in some patients. The risk factors for this are unknown.
To explore risk of paradoxical eczema by biologic class and identify factors associated with paradoxical eczema.
This prospective cohort study used data from the British Association of Dermatologists Biologics and Immunomodulators Register for adults treated with biologics for plaque psoriasis who were seen at multicenter dermatology clinics in the UK and Ireland. Included participants were registered and had 1 or more follow-up visits between September 2007 and December 2022.
Duration of exposure to tumor necrosis factor (TNF) inhibitors, interleukin (IL) 17 inhibitors, IL-12/23 inhibitors, or IL-23 inhibitors until paradoxical eczema onset, treatment discontinuation, last follow-up, or death.
Incidence rates of paradoxical eczema, paradoxical eczema risk by biologic class, and the association of demographic and clinical variables with risk of paradoxical eczema were assessed using propensity score-weighted Cox proportional hazards regression models.
Of 56 553 drug exposures considered, 24 997 from 13 699 participants were included. The 24 997 included exposures (median age, 46 years [IQR, 36-55 years]; 57% male) accrued a total exposure time of 81 441 patient-years. A total of 273 exposures (1%) were associated with paradoxical eczema. The adjusted incidence rates were 1.22 per 100 000 person-years for IL-17 inhibitors, 0.94 per 100 000 person-years for TNF inhibitors, 0.80 per 100 000 person-years for IL-12/23 inhibitors, and 0.56 per 100 000 person-years for IL-23 inhibitors. Compared with TNF inhibitors, IL-23 inhibitors were associated with a lower risk of paradoxical eczema (hazard ratio [HR], 0.39; 95% CI, 0.19-0.81), and there was no association of IL-17 inhibitors (HR, 1.03; 95% CI, 0.74-1.42) or IL-12/23 inhibitors (HR, 0.87; 95% CI, 0.66-1.16) with risk of paradoxical eczema. Increasing age (HR, 1.02 per year; 95% CI, 1.01-1.03) and history of AD (HR, 12.40; 95% CI, 6.97-22.06) or hay fever (HR, 3.78; 95% CI, 1.49-9.53) were associated with higher risk of paradoxical eczema. There was a lower risk in males (HR, 0.60; 95% CI, 0.45-0.78).
In this study, in biologic-treated patients with psoriasis, paradoxical eczema risk was lowest in patients receiving IL-23 inhibitors. Increasing age, female sex, and history of AD or hay fever were associated with higher risk of paradoxical eczema. The overall incidence of paradoxical eczema was low. Further study is needed to replicate these findings.

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis

Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis

Clinical Summary

What was studied

Key findings

Clinical implications

Related Questions